Immunotherapy agent can disrupt viral reservoir in SIV-infected monkeys

February 25, 2016
Immunotherapy agent can disrupt viral reservoir in SIV-infected monkeys

An immune-enhancing treatment can push SIV (simian immunodeficiency virus) out of its hideouts in infected monkeys that have the virus controlled with drugs, scientists at Yerkes National Primate Research Center, Emory University report.

The results were presented on Wednesday, February 24 at the Conference on Retroviruses and Opportunistic Infections in Boston by graduate student Geetha Mylvaganam.

Rama Rao Amara, PhD, professor of microbiology and immunology at Yerkes and the Emory Vaccine Center, led the project. Collaborators include Rafi Ahmed, PhD, director of Emory Vaccine Center and a Georgia Research Alliance Eminent Scholar, and Gordon Freeman, PhD, of Dana-Farber Cancer Institute. Mylvaganam is part of the Immunology and Molecular Pathogenesis graduate program at Emory.

Antiretroviral drugs can usually control HIV in chronically infected people, but they can't completely eliminate it. That's because some immune cells harboring the virus remain dormant. A strategy has emerged called "shock and kill" or "kick and kill", aimed at activating those cells, so that the virus can be flushed out.

The Yerkes team tested the effects of blocking PD-1, a molecule that inhibits the immune response during chronic infections, in combination with antiretroviral therapy. Antibodies that block PD-1 have also been tested, with some success, as cancer immunotherapy agents. The team developed a "primatized" anti-PD-1 antibody, to reduce monkeys' immune responses to the antibody itself and enable repeated infusions.

With some SIV-infected monkeys, the researchers treated them with anti-PD-1 antibody for 14 days, starting from 10 days before antiretroviral therapy began. In this situation, the anti-PD-1-treated animals showed more rapid viral suppression (average 42 days in the PD-1 group versus 140 days in controls) and more active antiviral T cells.

In addition, other SIV-infected monkeys were treated with anti-PD-1 antibody (three infusions, with a month between each) after had brought viral levels to a very low level. This resulted in transient reappearances of SIV in their blood, not seen in control animals.

The researchers conclude:

"These results reveal for the first time the potential of PD-1 blockade, both on restoring anti-viral CD8 T cell function, and possibly destabilizing the viral reservoir under ART. They highlight the potential of PD-1 blockade to work synergistically with other therapeutic agents such as vaccines and latency reversing agents to effectively diminish HIV reservoir under ART as a means to establish a functional cure."

Explore further: Scientists discover effects of PD-1 blockade on ART therapy in SIV-infected monkeys

Related Stories

Scientists discover effects of PD-1 blockade on ART therapy in SIV-infected monkeys

March 8, 2012
Scientists have discovered that blocking PD-1 (programmed death-1), an immune molecule that inhibits the immune response to viral infections, can have a significant effect on HIV-like illness in nonhuman primates.

IL-21 repairs immune function in primate model of HIV infection

November 9, 2015
Antiretroviral drugs can suppress HIV for years, but a residual inflammatory imbalance contributes to health problems in infected individuals who are infected with the virus. A novel combination treatment aimed at repairing ...

Overcoming immune exhaustion from chronic HIV infection

December 3, 2015
Chronic HIV infection results in exhaustion of the immune system, a phenomenon characterized by dysfunctional HIV-specific killer T cells. The exhausted T cells display inhibitory proteins on their surface, and scientists ...

SIV shrugs off antibodies in vaccinated monkeys

August 11, 2015
New research on monkeys vaccinated against HIV's relative SIV calls into question an idea that has driven AIDS vaccine work for years. The assumption: a protective vaccine only needs to stimulate moderate levels of antibodies ...

Immune cells proposed as HIV hideout don't last in primate model

October 31, 2014
Where does HIV hide? Antiretroviral drugs can usually control the virus, but can't completely eliminate it. So any strategy to eradicate HIV from the body has to take into account not only the main group of immune cells the ...

HIV antibody infusion safely suppresses virus in infected people

December 23, 2015
A single infusion of a powerful antibody called VRC01 can suppress the level of HIV in the blood of infected people who are not taking antiretroviral therapy (ART), scientists at the National Institutes of Health report in ...

Recommended for you

Scientists find where HIV 'hides' to evade detection by the immune system

October 19, 2017
In a decades-long game of hide and seek, scientists from Sydney's Westmead Institute for Medical Research have confirmed for the very first time the specific immune memory T-cells where infectious HIV 'hides' in the human ...

National roll-out of PrEP HIV prevention drug would be cost-effective

October 18, 2017
Providing pre-exposure prophylaxis (PrEP) medication to men who have sex with men who are at high risk of HIV infection (equivalent to less than 5% of men who have sex with men at any point in time) in England would be cost-effective, ...

Regulatory T cells harbor HIV/SIV virus during antiviral drug treatment

October 17, 2017
Scientists at Yerkes National Primate Research Center, Emory University have identified an additional part of the HIV reservoir, immune cells that survive and harbor the virus despite long-term treatment with antiviral drugs.

New research opens the door to 'functional cure' for HIV

October 17, 2017
In findings that open the door to a completely different approach to curing HIV infections, scientists from the Florida campus of The Scripps Research Institute (TSRI) have for the first time shown that a novel compound effectively ...

Researchers create molecule that could 'kick and kill' HIV

October 5, 2017
Current anti-AIDS drugs are highly effective at making HIV undetectable and allowing people with the virus to live longer, healthier lives. The treatments, a class of medications called antiretroviral therapy, also greatly ...

A sixth of new HIV patients in Europe 50 or older: study

September 27, 2017
People aged 50 and older comprise a growing percentage of HIV patients in Europe, accounting for one in six new cases in 2015, researchers said Wednesday.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.